Logo

Iconix Signs Chemogenomics Collaboration with Icos

Jun 24, 2004

NEW YORK, June 24 (GenomeWeb News) - Iconix Pharmaceuticals will provide its chemogenomic profiling technology to Icos, the Mountain View, Calif.-based company said today.

 

Under the agreement, Icos will use Iconix's chemogenomics platform to study preclinical drug responses and to discover biomarkers to predict drug efficacy and side effects.

 

Iconix will use its Drug Signature collection of predictive biomarkers, derived from its DrugMatrix chemogenomics reference database.

Breaking News
The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.